Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.